New therapeutics for E6AP-associated disorders
LSU Health Sciences Center - New Orleans, Louisiana, United States
A team of investigators have discovered a novel small-molecule for the treatment of HPV-associated cervical cancer, hepatitis C pathology, and certain instances of Autism Spectrum Disorder. The molecular target, binding site, and mechanism of action of this therapeutic have been characterized. Proof-of-principle studies showing efficacy and specificity have been completed.
Primary Application Area: Pharmaceuticals & Personal Care
Technology Development Status: Prototype
Technology Readiness Level: TRL 3
FIGURES OF MERIT
Value Proposition: This technology leverages the identification of a previously unknown mechanism required for E6AP activity into the development of a therapeutic for E6AP-associated disorders. Proof-of-principle studies have already been performed, presenting a pharmaceutical company a unique opportunity to optimize a lead compound into a marketable therapeutic.
Organization Type: Academic/Gov Lab
Showcase Booth #: 737
GOVT/EXTERNAL FUNDING SOURCES
Government Funding/Support to Date: NIH GM034009
Primary Sources of Funding: Federal Grant, University
Looking for: Both Funding and Development Partners